Scarica l'app Stockscreener
2.75
0.72%
-0.02
Pre-mercato:
2.80
0.05
+1.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.77
Aprire:
$2.77
Volume 24 ore:
3.00M
Relative Volume:
0.54
Capitalizzazione di mercato:
$849.19M
Reddito:
$348.97M
Utile/perdita netta:
$5.86M
Rapporto P/E:
163.69
EPS:
0.0168
Flusso di cassa netto:
$13.69M
1 W Prestazione:
+7.42%
1M Prestazione:
-0.72%
6M Prestazione:
-48.60%
1 anno Prestazione:
-39.29%
Intervallo 1D:
$2.68
$2.7705
Intervallo di 1 settimana:
$2.55
$2.775
Portata 52W:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.75 | 855.36M | 348.97M | 5.86M | 13.69M | 0.0168 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-10-10 | Iniziato | Leerink Partners | Outperform |
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development - Insider Monkey
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MNKD Maintains Rating by Mizuho -- Price Target Lowered to $8.00 - GuruFocus
Leerink reiterates Outperform on MannKind stock, sees overreaction - Investing.com
Leerink reiterates Outperform on MannKind stock, sees overreaction By Investing.com - Investing.com UK
Risk Check: Is MannKind Corporation in a bullish channel2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
MannKind (NASDAQ: MNKD) details 2026 virtual meeting, board elections and pay vote - Stock Titan
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
Q4 2025 MannKind Corp Earnings Call Transcript - GuruFocus
MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
Q2 2025 MannKind Corp Earnings Call Transcript - GuruFocus
Truist reiterates MannKind stock rating on partner trial data By Investing.com - Investing.com India
Truist reiterates MannKind stock rating on partner trial data - Investing.com
Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? - Insider Monkey
Vanguard disaggregates holdings; MannKind (MNKD) shows 0 shares in 13G/A - Stock Titan
MannKind (MNKD) EVP receives new performance RSU and option awards - Stock Titan
MannKind (MNKD) awards performance RSUs and stock options to officer - Stock Titan
MannKind (MNKD) awards EVP Singh performance RSUs and stock options - Stock Titan
Setup Watch: Is now the right time to enter MannKind CorporationTrend Reversal & Smart Allocation Stock Reports - baoquankhu1.vn
How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential - Yahoo Finance
Chart Watch: Whats the beta of MannKind Corporation stockMarket Risk Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MannKind Corp. Hits Day Low of $3.29 Amid Price Pressure - Markets Mojo
MannKind Corp stock hits new 52-week low on NASDAQ amid analyst downgrades and earnings miss - AD HOC NEWS
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's What Happened - MarketBeat
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
MannKind Corp. Stock Plummets to New 52-Week Low of $3.29 - Markets Mojo
Portfolio Update: Is MannKind Corporation in a bullish channel2026 Selloffs & Scalable Portfolio Growth Ideas - baoquankhu1.vn
(MNKD.O) | Stock Price & Latest News - Reuters
MannKind Corp Stock (ISIN: US5638651064) Faces Pressure Amid Biotech Selloff and Analyst Cuts - AD HOC NEWS
MannKind (NASDAQ:MNKD) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Why MannKind Needs Your Attention - RTTNews
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
Insider Stock Purchases: March 11, 2026 | FOUR Stock News - Quiver Quantitative
MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma - Investing.com
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock - MarketBeat
MannKind (NASDAQ: MNKD) CEO purchases 100,000 shares in market trade - Stock Titan
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - The Manila Times
MannKind presents Afrezza data at diabetes conference - Investing.com
MannKind Corporation to Present Data on Inhaled Insulin Afrezza at ATTD 2026 Conference - Quiver Quantitative
Afrezza needle-free insulin for kids heads for FDA decision May 29, 2026 - Stock Titan
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance
Vanguard Group Inc. Has $94.68 Million Holdings in MannKind Corporation $MNKD - MarketBeat
MannKind settles $36.3M convertible notes with cash, shares By Investing.com - Investing.com Canada
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Re - GuruFocus
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
MannKind closes note deal with $35.5M cash and 569,023 shares - Stock Titan
Wedbush Lowers Price Target for MannKind (MNKD) While Maintainin - GuruFocus
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):